Cancers, Vol. 15, Pages 5291: Clinical Advances and Future Directions of Oncolytic Virotherapy for Head and Neck Cancer

Cancers, Vol. 15, Pages 5291: Clinical Advances and Future Directions of Oncolytic Virotherapy for Head and Neck Cancer

Cancers doi: 10.3390/cancers15215291

Authors: Zhan Wang Peng Sun Zhiyong Li Shaowen Xiao

Oncolytic viruses (OVs), without harming normal tissues, selectively infect and replicate within tumor cells, to release immune molecules and tumor antigens, achieving immune-mediated destruction of tumors and making them one of the most promising immunotherapies for cancer. Many clinical studies have demonstrated that OVs can provide clinical benefits for patients with different types of tumors, at various stages, including metastatic and previously untreatable cases. When OVs are used in combination with chemotherapy, radiotherapy, immunotherapy, and other treatments, they can synergistically enhance the therapeutic effects. The concept of oncolytic virotherapy (OVT) was proposed in the early 20th century. With advancements in genetic engineering, genetically modified viruses can further enhance the efficacy of cancer immunotherapy. In recent years, global research on OV treatment of malignant tumors has increased dramatically. This article comprehensively reviews the findings from relevant research and clinical trials, providing an overview of the development of OVT and its application in the clinical treatment of head and neck cancer. The aim is to offer insights for future clinical and fundamental research on OVT.